Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2006-10-01
Metadata
Show full item recordCitation
Parkinsonism Relat Disord. 2006, 12(7):443-52Abstract
A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to €12 000-64 000 according to cost-per-QALY thresholds of €38 000-70 000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldAdditional Links
http://dx.doi.org/10.1016/j.parkreldis.2006.04.006ae974a485f413a2113503eed53cd6c53
10.1016/j.parkreldis.2006.04.006
Scopus Count
Collections
Related articles
- [Cost and quality aspects in the treatment of Parkinson's disease].
- Authors: Müller T, Dodel R, Fritze J
- Issue date: 2006
- Societal value of stem cell therapy in stroke--a modeling study.
- Authors: Svensson J, Ghatnekar O, Lindgren A, Lindvall O, Norrving B, Persson U, Kokaia Z
- Issue date: 2012
- A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
- Authors: Gupta OP, Brown GC, Brown MM
- Issue date: 2008 May
- Cost-utility analysis of Parkinson's disease.
- Authors: Shan DE, Wu HC, Chan LY, Liu KD
- Issue date: 2011 Mar
- Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
- Authors: Valldeoriola F, Morsi O, Tolosa E, Rumià J, Martí MJ, Martínez-Martín P
- Issue date: 2007 Nov 15